Price still isn’t right for Biogen’s blockbuster drug
HSE says Spinraza drug for SMA sufferers would cost €38 million over five years, as pharma giant clocks up global annual sales of $1.72 billion
Biogen’s Spinraza clocked up global sales of $1.72 billion for the company last year.
It is being reimbursed by numerous health systems across Europe - but to varying degrees.
The HSE told Biogen that it would not reimburse Spinraza at the price it was offering.
The original price - or list price - proposed by Biogen was €83,300 per 12 mg vial.
According to Professor Michael Barry, the medicines watchdog, the cost per ...
